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Abstract: Background: Major Depression (MD) and treatment-resistant depression (TRD) are worldwide leading causes 
of disability and therapeutic strategies for these impairing and prevalent conditions include pharmacological augmentation 
strategies and brain stimulation techniques. In this perspective, repetitive transcranial magnetic stimulation (rTMS) is a 
non-invasive brain stimulation technique with a favorable profile of tolerability which, despite being recently approved by 
the Food and Drug Administration (FDA) for the treatment of patients with medication-refractory unipolar depression, 
still raises some doubts about most effective parameters of stimulation. Methods: A literature search was performed using 
PubMed for the years 2001 through February 2011 in order to review meta-analytic studies assessing efficacy and safety 
issues for rTMS in depressive disorders. Fifteen meta-analyses were identified and critically discussed in order to provide 
an updated and comprehensive overview of the topic with specific emphasis on potentially optimal parameters of  
stimulation. Results: First meta-analyses on the efficacy of rTMS for the treatment of MD and TRD have shown mixed 
results. On the other hand, more recent meta-analytic studies seem to support the antidepressant efficacy of the technique 
to a greater extent, also in light of longer periods of stimulation (e.g. > 2 weeks). Conclusion: rTMS seems to be an  
effective and safe brain stimulation technique for the treatment of medication refractory depression. Nevertheless, further 
studies are needed to better define specific stimulation-related issues, such as duration of treatment as well as durability of 
effects and predictors of response. 
Keywords: Transcranial magnetic stimulation (rTMS), major depression (MD), treatment-resistant depression (TRD),  
meta-analyses. 
INTRODUCTION 
Treatment Resistant Depression (TRD) and Therapeutic 
Options 
Major Depression (MD) is a severe and disabling  
condition with high levels of morbidity and mortality. 
Unfortunately, only about 50% of patients affected by MD 
respond to an initial course of antidepressants. For non-
responder subjects, strategies for achieving response include 
antidepressant switches, combination or augmentative 
therapies with different class of antidepressants, mood 
stabilizers, atypical antipsychotics and/or other psychotropic 
compounds. These options are not always well accepted by 
patients because of side effects, like weight gain and sexual 
dysfunctions, particularly in the long-term treatment. It has 
been estimated that approximately 2% to 15% of all patients 
with MD are refractory to any pharmacological treatment 
according to the specific adopted criteria [1, 2]. For instance, 
treatment-resistant depression (TRD) has been defined as the 
lack of response to two antidepressant trials, given in  
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succession, at adequate doses and for an adequate time 
frame, in compliant subjects [3]. For these patients, different 
treatment strategies are available, including pharmacological 
and psychotherapic augumentations as well as brain stimula-
tion techniques [4]. The latters include electroconvulsive 
therapy (ECT), transcranial magnetic stimulation (TMS), 
deep brain stimulation (DBS), transcranial direct current 
stimulation (tDCS) and vagus nerve stimulation (VNS) [5]. 
Recently, among these techniques - which have different 
rationale, level of invasiveness and profile of tolerability - 
repetitive TMS (rTMS) was approved by the Food and Drug 
Administration for the treatment of “patients with medica-
tion-refractory unipolar depression who have failed one 
good, but no more than one, pharmacological trial”.  
TMS has been introduced as neurophysiological tech-
nique in 1985, when Anthony Barker and his team developed 
a compact machine that allowed non-invasive stimulation of 
the cerebral cortex. Since its introduction, TMS has been 
used for the evaluation of the motor system, for functional 
studies of different brain areas and for the physiological 
study of several neuropsychiatric illness. Actually, over the 
last years, an increasing number of centers have started of-
fering TMS for the treatment of different diseases, Major 
Depression in particular, condition TMS has already ap-
proved for in some countries. As a matter of fact, TMS has 
been considered by many clinicians even safer and better 
168     Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7 Dell’Osso et al. 
tolerated than many other pharmacological options or brain 
stimulation interventions (such as ECT) [6]. Nevertheless, 
questions about the magnitude of its antidepressant effect 
and about predictors of response in patients with TRD still 
remain open [7]. For instance, it has been established that a 
lower number of prior failed antidepressant treatments is 
associated with a better clinical outcome in relation to rTMS 
[8].  
TMS: Background and Rationale 
TMS generates a brief and intense magnetic field created 
by a strong electric current circulating within a coil resting 
on the scalp [9]. The powerful magnetic fields act as a vector 
that passes unimpeded across the skull and then converts into 
an electrical field within the brain. This procedure of brain 
stimulation through the scalp is not invasive and does not 
cause any pain at the surface [10]. The induced electrical 
stimulus activates a mixture of neurons beneath the coil. The 
magnetic field falls off rapidly with distance from the coil, 
so it is usually assumed that the stimulus activates neural 
elements in the cortex or subcortical white matter [11]. The 
stimulus, according to the stimulation intensity, is able to 
activate cortical neurons at a depth of 1.5-3.0 cm beneath the 
scalp. When using intensities below 120% of motor thresh-
old, the stimulation cannot induce direct activation at depth 
of more than 2 cm [6]. Neuronal axons, rather than their cell 
bodies, are the most likely target of the stimulus as they have 
the lowest threshold for activation to the brief electrical cur-
rent induced by TMS. However, coils with deeper power of 
stimulation have been recently introduced [12]. Different 
neurons have distinct threshold to electrical stimulation; low 
stimulation intensities, therefore, activate a much more lim-
ited selection of neurons than higher intensities. Most of our 
knowledge about the action of TMS on the human cortex 
comes from studies of the primary motor cortex. Stimulation 
of this area evokes activity in the muscle on the opposite side 
of the body, which is easily measured using electrophysi-
ological methods. TMS of the motor cortex can detect the 
resting motor threshold and shows that the size of the re-
sponse depends on the level of activity in the cortex at the 
time the stimulus is given and on the orientation of the coil 
on the head. TMS can be applied one stimulus at a time (sin-
gle-pulse TMS), in pairs of stimuli separated by a variable 
interval (paired-pulse TMS), or in trains which is the most 
common stimulation setting used in psychiatric clinical prac-
tice (rTMS) [8]. Single pulses of TMS produce complex but 
short responses. Repeated pulses can have more prolonged 
effects on the modulation of cortical excitability, decreasing 
or increasing it. Relatively short-term effects (of the order of 
seconds or few minutes) are probably due to changes in neu-
ronal excitability caused by shifts in ionic balance around 
populations of active neurons. Longer-lasting effects last 
usually 30-60 minutes and appear to depend on synaptic 
changes among cortical neurons, also known as long-term 
depression (LTD) and long-term potentiation (LTP) of syn-
aptic connection. There is good evidence that changes result-
ing from TMS influence natural behaviours and have thera-
peutic potential. The nature of the after-effects of TMS de-
pends on the site of stimulation and on the frequency, num-
ber and intensity of stimulation pulses, as well as on the pat-
tern of the applied pulses [11].  
The frequency at which the magnetic field oscillates dif-
fers between studies. Although different studies have used 
various frequencies, two main types have been used: low (1 
Hz) and high frequency (>1 Hz). The two types of stimula-
tions have opposite effects and left and right hemispheres are 
supposed to have contrasting roles in mood regulation [13]. 
In particular, patients with depression seem to have reduced 
activity in the left prefrontal cortex. Therefore, many rTMS 
studies have been designed to excite this area with high-
frequency stimulation and to achieve a long-lasting effect by 
applying rTMS during several daily sessions. More recently, 
investigators have focused on the hypotesis that in depressed 
patients there is an imbalance in the activity of the frontal 
lobes, with hypofunction in the left frontal lobe caused by 
excessive inhibition from the right one. This led to the idea 
that an alternative treatment would be low-frequency (sup-
pressive) rTMS of the right prefrontal cortex [11]. Patterned 
rTMS refers to repetitive application of short rTMS bursts at 
a high inner frequency separated by short pauses of no 
stimulation. To date, most used protocols of this kind are the 
different theta burst stimulations (TBS) in which short bursts 
of 50 Hz are repeated at a rate in the theta range (5 Hz) as a 
continuous (cTBS) or intermittent (iTBS) train. In order to 
comply with present safety guidelines, protocols of slow 
rTMS generally apply all pulses in a continuous train, 
whereas protocols of fast rTMS apply shorter periods of 
stimulation separated by periods of pause. Obviously, there 
is a large variety of combinations of such protocols. Re-
cently, quadripulse stimulation (QPS) has been added to pat-
terned rTMS procedures to induce long-term changes of cor-
tical excitability.  
TMS in Clinical Practice 
Several clinical trials have confirmed the overall safety 
of rTMS [14]. Induction of seizures is the most acute adverse 
effect; however, considering the small number of cases of 
accidental seizures induced by rTMS reported to date, the 
risk is certainly very low. More often than seizures, 
vasodepressor syncope may occur during TMS testing and 
treatment, due to anxiety and psycho-physical discomfort. 
Mania and hypomania have been reported in few bipolar and 
unipolar patients treated with TMS [15]. More frequently, 
minor side effects such as discomfort during the stimulation, 
local pain, neck pain, transient hearing changes and head-
ache after stimulation, may occur [6].  
Taken as a whole, the efficacy and safety of rTMS led 
the FDA, in October 2008, to approve a specific rTMS de-
vice that “is indicated for the treatment of Major Depressive 
Disorder in adult patients who have failed to achieve  
satisfactory improvement from one prior antidepressant 
medication at or above the minimal effective dose and dura-
tion in the current episode” [16]. This approval represents an 
important step forward for the diffusion of rTMS in the US 
and worldwide and should encourage further research. 
With respects to predictors of response to rTMS, subjects 
with psychotic depression, those with depressive episode of 
longer duration, elderly subjects (prefrontal atrophy in-
creases the distance between the coil and the cortex) and 
subjects with high degree of treatment resistance may be less 
likely to respond to rTMS [17]. Preliminary evidence sug-
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gests that clinical response to rTMS might itself be a predic-
tor of the success of future treatments [13]. 
Given the robust number of clinical trials conducted with 
rTMS over the last decade, several meta-analyses have been 
progressively performed on the efficacy and safety of the 
technique. 
The present review article was aimed to asses the effi-
cacy and safety of rTMS in MD and TRD, in particular, pro-
viding an updated and comprehensive overview in the field. 
Specific emphasis was given on the comparison between 
recent and earlier rTMS studies and meta-analyses in order 
to evaluate changes in the efficacy of the technique due to a 
better definition of stimulation parameters in recent years. In 
fact, 10-year experience with rTMS in the treatment of MD 
should have optimized the parameters of stimulation, result-
ing in larger clinical effects as documented in recent trials 
using novel parameters of stimulation, such as more sessions 
or different intensity of stimulation [18].  
MATERIALS AND METHODOLOGY 
Study Selection 
Articles for inclusion were identified conducting a litera-
ture search in PubMed in the period between January 1980 
and December 2010. Search criteria were: “transcranial 
magnetic stimulation”, “TMS”, “rTMS”, “depression”, “ma-
jor depression, “depressive disorders”, “treatment resistant 
depression” and “dysthymic disorder”. Only papers pub-
lished in English language were taken into account. For the 
purpose of our study, we decided to focus our attention on 
meta-analyses and systematic reviews, in particular. All re-
viewed studies included meta-analysis and randomized clini-
cal trials (RCTs) that compared rTMS given at any fre-
quency and localization, and controlled with sham interven-
tion, in patients of any age and gender with a diagnosis of 
MD according to the DSM-IV criteria or treatment resistant 
depression [19, 20]. Meta-analysis is a statistical technique 
for amalgamating, summarizing and reviewing previous 
quantitative research. By using meta-analysis, a wide variety 
of questions can be investigated, as long as a reasonable 
body of primary research studies exist. Selected parts of the 
reported results of primary studies are entered into a database 
and this "meta-data" is "meta-analyzed", in similar ways to 
working with other data descriptively and then inferentially 
to test certain hypotheses. 
RESULTS 
Fifteen meta-analyses were retrieved (from 2001 to 
2010), reviewed and summarized (Table 1).  
 
APPENDICES 
Table I. Summary of Metanalytic Studies (Focused on Efficacy) with rTMS Conducted in Major Depression to Date 
Study Methods Stimulation Parameters Conclusions and Limitations 
McNamara et al., 2001 Number of trials:5 
Avarage number of subjects 
per trial: 20-68 
Total number of patients: 151 
Site: 3 left DLPC, 1 right DLPC, 1 
bilateral stimulation 
Frequency:1-20 Hz 
rTMS had beneficial effects on depression. There 
was insufficient evidence to evaluate effect of rTMS 
on mania and schizophrenia. 
The duration of the antidepressant effects could not 
be established. 
Small number of trials. 
Difficulty in blinding. 
Holtzheimer et al., 2001 Number of trials: 12 Site: left and right DLPC (and 
sham) 
rTMS was statistically superior to sham stimulation 
in the treatment of depression, showing a moderate 
to large effect size. The clinical significance of these 
results was modest. 
Kozel and George, 2002 Number of trials:12 
Avarage number of subjects 
per trial: 6-35 
Total number of patients: 230 
Duration: 2 studies of 1 week and 10 
of 2 weeks 
Site: 12/12 left DLPFC  
Frequency: 0.3-20 Hz 
Intensity: 80-110% 
There was a statistically significant evidence that left 
DLPFC rTMS stimulation was an acute antidepres-
sant treatment. 
Limits: small number of subjects per trial, different 
parameters of stimulation, heterogeneity of the sam-
ple.  
Martin et al., 2001 Number of trials: 16 
Average number of subjects 
per trial: 19 
Duration: 1 or 2 weeks; 
Site: Left and right DLPFC, right 
DLPFC (and sham). 
Positive global effect (HDRS) in favor of high-
frequency, left sided rTMS vs sham after 2 weeks. 
This positive effect disappeared when using the BDI 
scale. Small sample size. No description of method 
of concealment allocation used. Double-blind re-
ferred to patient outcome assessor. 
Burt et al., 2002 (first 
analysis) 
Open and uncontrolled 
TMS studies 
Number of trials: 13 
Average number of subjects 
per trial: 16 
Total number of patients: 208 
Duration: 1-3 weeks; 
Site: Vertex, left and right DLPFC, 
RF TMS, Motor area, bilateral 
DLPFC TMS; 
Frequency: from 0,033 to 20 HZ; 
Intensity: 80-130% or 1-2,5 T. 
9 studies reported quantitative change in depression 
scores (HRSD and MADRS) but their average reduc-
tion was only 37% and the degree of therapeutic 
change was relatively modest. 
It should not be assumed that all studies derived from 
the same population with the same characteristics. 
(second analysis) 
Randomized, controlled 
studies 
Number of trials: 23 
Average number of subjects 
per trial: 19 
Total number of patients: 432 
Duration: 1-2 weeks; 
Site: Vertex, (frontal, temporal and 
parietal) left and right DLPFC (and 
sham); 
Frequency: from 0,17 to 40 Hz; 
Intensity: 80-110% or 0,015-1,9 T 
Slow and fast rTMS seemed to have statistically 
superior antidepressant effects compared to sham but 
the magnitude of the effects was of doubtful clinical 
significance. The analysis of variance comparing 
slow and fast rTMS did not yield a significant be-
tween-class effect. 
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Table I. contd…. 
Study Methods Stimulation Parameters Conclusions and Limitations 
 (third analysis) Ran-
domized trials compar-
ing rTMS and ECT 
Number of trials: 3  
Average number of subjects 
per trial: 37 Total number of 
patients: 112 
Duration: 2-4-weeks; 
Site: left DLPFC; 
Frequency: 10-20 Hz; 
Intensity: 90-100%. 
The meta-analysis of the 3 rTMS/ECT comparisons 
favoured ECT but there was not a statistically sig-
nificant advantage for ECT over rTMS, nor was there 
significant heterogeneity in effect size. The fact that 
this analysis is based only on 3 studies is a potential 
limitation.  
Martin et al., 2003 Number of trials: 14 
Total number of patients: 394 
Duration: 1 or 2 weeks; 
Site: Left and right DLPFC (and 
sham). 
Intensity: 80%-110%. 
A significant advantage in favor of the active high 
frequency and left-sided treatment after two weeks 
(HRSD). Overall low methodological quality 
Couturier, 2005 Number of trials: 6 
Average number of subjects 
per trial: from 6 to 30; 
Total number of patients: 91 
Duration: 1-2 weeks; 
Site: left DLPFC (and sham); 
Frequency: 10-20 Hz; 
Intensity: 80-100%. 
Rapid-rate rTMS as efficacious as sham therapy in 
treating adults with a major depressive episode. 
Overall low statistical power. 
Herrmann et al., 2006 Number of trials: 33 
Total number of patients: 877 
Duration: 1 or more weeks, 
Site: left DLPFC (26/33) and right 
DLPFC (3/33) and bilateral stimula-
tion. 
Frequency: less or more than 15 Hz 
Intensity: 80-100%.  
rTMS was more effective than sham in the treatment 
of depression. 
No outcome predictor that clearly predicted rTMS 
efficacy was found. 
No significant bias were found. 
Limit: efficacy was examined only immediately after 
TMS treatment and not at follow-up. 
Gross et al.. 2007 Number of trials: 5 
Average number of subject 
per trial: from 27 to 99 
Total number of patients: 274 
Duration: 2-3 weeks; 
Site: left and right DLPFC, bilateral 
(and sham); 
Frequency:1-15Hz 
Intensity: 90-110% 
Recent trials show larger antidepressant effect when 
compared to earlier meta-analysis.  
The number of sessions may be an important pa-
rameter to predict the clinical effect of rTMS.  
Small number of included studies. 
Lam et al. 2008 Number of trials: 24 
Average number of subjects 
per trial: from 10 to 301 
Total number of patients: 
1092  
Duration: 1-4 weeks; 
Site: Left and right DLPFC, bilateral 
(and sham); 
Frequency: 1-20 Hz; 
Intensity: 80-120%  
Active rTMS was significantly superior to sham over 
short-term treatment of TRD (1-4 weeks) but the 
overall response and remission rates were low and it 
is unclear whether the effects were sustained. 
Different follow- up periods. 
Shutter, 2009 Number of trials: 30 
Total number of patients: 
1164  
Duration: 1-4 weeks; 
Site: Left DLPFC (and sham); 
Frequency: 5-20 Hz; 
Intensity: <100-120%. 
Active rTMS was significantly more efficacious than 
sham treatment. 
Treatment resistance or intensity of rTMS do not 
play a major role in the antidepressant effect 
Shutter, 2010 Number of trials: 9 
Average number of subject 
per trial:12-70 
Total number of patients : 
243 
Duration:1-3 weeks 
Site: vertex (1 study), left PFC (2 
studies), right PFC(5 studies), bilat-
eral PFC (1 study) 
Frequency:0.25-1 Hz 
Intensity: 90-110% 
Slow frequency rTMS was more effective than sham 
in the treatment of MDD and as effective as fast 
frequency rTMS. There was no sufficient evidence to 
suppose the efficacy of slow-frequency bilateral 
stimulation.  
Limits: small number of studies, different target of 
stimulation used,  
Slotema et al., 2010 Numbers of trials: 40 (34 
rTMS vs sham, 6 rTMS vs 
ECT) 
Avarage number of subject 
per trial: 6-301 
Total number of patients: 
1562 
Duration:1-5 weeks 
Site: left PFC (30 studies), right PFC 
(3 studies), bilateral PFC (7 studies) 
Frequency: 0.3-10 Hz 
Intensity: 80-120% 
rTMS was more effective than sham treatment, but 
less than ECT.  
RTMS as monotherapy and low-frequency right-
sided sTMS showed a trend toward better results. 
Limits: different definitions of “treatment resistant 
depression” were used in included studies. Several 
studies showed the number of dropout but not the 
reason. 
DLPFC: Dorso-Lateral-Pre-Frontal Cortex; Hz: Hertz; rTMS: repetitive Transcranial Magnetic Stimulation; HDRS: Hamilton Depression Rating Scale; BDI: Beck Depression Inven-
tory; TRD: Treatment Resistant Depression 
 
The first meta-analysis conducted by Martin and  
co-workers in 2001 [21] was aimed to assess the clinical 
efficacy and safety of the technique in MD. Sixteen RCTs 
were included and participants were patients with unipolar or 
bipolar depression in depressed phase. Fourty-five trials 
were excluded because of lack of or inadequate randomiza-
tion, lack of a sham group, narrative review or descriptive 
studies with healthy volunteers. Different stimulation pa-
rameters were used. Of note, the mean duration of treatment 
was of 2 weeks. Several biases were found in the included 
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studies so that the quality of this meta-analysis could not be 
optimal. In fact, some of these trials did not describe the ran-
domization procedure making it difficult to blind the profes-
sionals who applied stimulation. For this reason, double-
blind design in these cases generally refers to the patient and 
to the outcome assessor (blind-rater design) and not to the 
clinician who performs the stimulation. Other limits were the 
small sample size of the studies (median = 19 subjects), the 
use of different follow-up periods and the heterogeneity of 
the disorder. The Hamilton Rating Scale for Depression 
(HRSD) [22] was used as a primary outcome measure and 
authors found a positive global effect in the comparison be-
tween high-frequency, left sided TMS vs placebo after 2 
weeks. However, this positive effect disappeared when using 
the Beck self-applied questionnaire (BDI) [23]. In addition, 
low frequency, right-sided rTMS appeared more effective 
than sham after 2 weeks of treatment (but not at one week). 
Finally, when rTMS was compared to ECT, significant dif-
ferences appeared in favor of ECT only when patients had 
psychotic symptoms. In conclusion, this meta-analysis sug-
gested that there was no strong evidence for a clear efficacy 
of TMS for the treatment of depression, even though the 
results did not exclude the possibility of benefit.  
In 2001, another meta-analysis by McNamara and col-
leagues assessed the effectiveness of rTMS in mood disor-
ders and schizophrenia [24]. Sixteen studies of rTMS in 
TRD were identified, but only 5 were analyzed being these 
conducted vs sham. In 3 studies rTMS was applied at 10-20 
Hz to the left frontal region. In one study it was applied at 1 
Hz to the right side and in the other trial both techniques 
were applied. Taken as a whole, these 5 trials enlisted 151 
patients: 81 were treated and 70 were in the control group. 
The duration of treatment varied between 1-4 weeks (2 
weeks of stimulation plus 2 weeks of sham). The overall chi-
squared test of association implied a statistically significant 
benefit of rTMS. The difference between rates of improve-
ment in the treated and control groups was 43%. In terms of 
tolerability and adverse events, no seizure was reported and 
the only side-effect was transient headache. The major limit 
consisted of the lack of a proper sham control. The duration 
of antidepressant effect after rTMS treatment, moreover, was 
not specifically defined in any of these studies and, finally, 
the small size of these trials represented another limitation. 
In conclusion, the authors reported a positive effect for TMS, 
but could not establish which stimulation parameters are the 
more effective and which patients are more likely to respond 
to the procedure. 
In the same year, Holtzheimer and colleagues (2001) 
identified 12 RCTs of TMS in MD, 11 of which identifying 
the left dorsolateral pre-frontal cortex (DLPFC) as stimula-
tion target. Fixed and random effects meta-analyses were 
performed on these studies comparing the decrease in HRSD 
scores obtained with rTMS and sham stimulation. However, 
given that initial results with a fixed-effects analysis failed 
homogeneity testing, a random-effects analysis was used to 
calculate all results. In 12 studies, the weighted mean effect 
size was 0.81. For studies using left DLPFC stimulation, the 
weighted mean effect size was 0.89 and, for studies using 
left DLPFC stimulation in a parallel-groups design (7 stud-
ies), the weighted mean effect size was 0.88. Of clinical in-
terest, no study showed a mean decrease in HRSD scores > 
50%; in fact, only few patients were considered HRSD re-
sponders after the overall stimulation (13.7% with rTMS vs 
7.9% with sham). Authors concluded that rTMS was statisti-
cally superior to sham stimulation in the treatment of depres-
sion, showing a moderate to large effect size. Nonetheless, 
authors remarked that the clinical significance of these re-
sults was modest [25].  
The study conducted by Burt and co-workers in 2002 
[26] included 3 distinct meta-analyses assessing effect size 
and magnitude of therapeutic effects of rTMS. The first 
meta-analysis was performed on open and uncontrolled trials 
of rTMS in the treatment of MD. Nine trials reported signifi-
cant quantitative changes in depression scores and the 
weighted effect size confirmed the antidepressant effect of 
both slow or fast rTMS. Nevertheless, the average reduction 
in HRSD and Montgomery-Asberg Depression Rating Scale 
(MADRS) scores was around 37% and the clinical signifi-
cance of this effect was uncertain. The second meta-analysis 
involved 23 sham or otherwise controlled studies with 
rTMS. Across these comparisons, the combined effect sizes 
indicated a moderate to large effect and there was only one 
comparison with a clearly negative effect size. Results indi-
cated that slow and fast rTMS had statistically superior anti-
depressant properties compared to sham stimulation. The 
analysis of variance in relation to slow and fast rTMS 
showed that higher frequency stimulation did not necessarily 
enhance the antidepressant effect. Despite these positive re-
sults, the effect size was not so impressive and the mean im-
provement in HRSD scores between active and control con-
dition was only 16%. Finally, in a third meta-analysis, 3 tri-
als which had randomly assigned depressed patients to 
treatment with rTMS or ECT were analyzed. Results indi-
cated that changes in the HRSD scores favored ECT over 
rTMS, but this difference was not statistically significant.  
In the same year, Kozel and George [27] selected 12 
randomized sham-controlled trials of left prefrontal rTMS in 
MD in their meta-analysis, with a total sample of 230 pa-
tients. The sample resulted homogeneous and the cumulative 
effect size was 0.53. Days of treatment varied from 5 to 10. 
The outcome variable for all included studies was defined as 
the change in HRSD score. The cumulative effect sizes were 
statistically significant and the improvement clinically meas-
urable, leading the authors to support the hypothesis that left 
rTMS over the DLPFC is an efficacious instrument to treat 
depression, in particular for acute treatment. Principal limita-
tions of this meta-analysis were the inclusion of studies with 
a small number of subjects and the heterogeneity of patients 
included. Moreover, data about duration of improvement and 
about the relationship between concomitant medication use 
and TMS effect were not reported. The authors concluded 
suggesting that the best parameters for treatment may depend 
on regional brain blood flow prior to treatment [28].  
In 2003, Martin and co-authors conducted another 
study to assess the efficacy of rTMS in MD by performing a 
systematic review of RCTs comparing rTMS with sham 
stimulation [29]. Fourteen trials were included according to 
the following criteria: all were randomized trials with rTMS 
given at any frequency and at any localization with a sham 
intervention in patients of any age and gender with a diagno-
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sis of unipolar or bipolar depression, with or without psy-
chotic symptoms according to DSM-IV or ICD-10 criteria. 
Forty-eight studies were excluded. Clinical heterogeneity in 
selected trials was due to differences in the target of stimula-
tion, duration of treatment and number of interventions per 
day (one or more). The majority of these studies compared 
left-sided, high-frequency rTMS with a sham group; only 
one study compared right-sided, low-frequency TMS with 
sham. In 9 studies treatment duration was 2 weeks, while in 
the others just 1 week. All studies used the HRSD as primary 
outcome measure and 9 used the BDI as well. Quality of 
most studies was generally low and the majority of them did 
not provide a precise description of randomization process 
and none described the method of concealing. Only 2 studies 
undertook an intention-to-treat analysis. Most studies pre-
sented as double-blind trials were, actually, single-blind tri-
als with blind-rater evaluations. Only 3 studies stated that 
patients had been free from antipsychotic medications for 1 
week before entering the study [30-32]. Other limitations 
were the small sample size of the selected studies (median = 
29 subjects) and the difficulty of interpreting results from 
psychometric scales [33]. In terms of results, a small effect 
was detected in favor of the active group when measured by 
HRSD after 2 weeks of high frequency, left-sided rTMS, but 
not at 2 weeks of follow-up.  
In 2005, a systematic review and meta-analysis by Cou-
turier [34] assessed the efficacy of rapid-rate rTMS in the 
treatment of MD on the basis of studies conducted from 
1966 until 2003. Criteria pertaining to intervention were a) 
rapid rTMS, high frequency (10 Hz), b) application over the 
left DLPFC, c) intensity (80%), and d) the presence of sham 
control. These inclusion criteria were satisfied by 6 studies 
(3 of which were crossover trials) which had a duration of 1 
or 2 weeks. The results indicated that rapid-rate rTMS was 
not more efficacious than sham therapy in treating depres-
sion. These results are different from those of a previous 
meta-analysis on 5 RCTs by McNamara and coworkers [24] 
who found a beneficial effect of rTMS compared with pla-
cebo, as shown before. In the Couturier’ meta-analysis, 3 
possible explanations for the lack of benefit for rTMS versus 
sham therapy were provided. The first one was simply that 
rTMS had a similar efficacy to sham. The second was the 
lack of definition of effective stimulation parameters of 
rTMS. In particular, Couturier suggested that at that time 
there was no evidence about the relevance of DLPFC as 
stimulation target. With respect to stimulation parameters of 
the trials included in the meta-analysis, particularly in rela-
tion to the duration of stimulation, it was maximum 2 weeks. 
Another confounding variable may have been the nature of 
sham condition, because inadequate sham procedure may 
partially stimulate the cortex, exerting possible therapeutic 
effects [35]. Finally, the author stressed the low statistical 
power of the 6 studies included in the analysis (too small 
samples despite being overall well-designed studies). Het-
erogeneity in these studies was not significant, indicating 
that data source was appropriate.  
A meta-analysis conducted by Herrmann’s group in 
2006 was aimed to investigate optimal parameters in relation 
to rTMS response through a literature search of controlled 
trials [36]. Thirty three TMS studies conducted on depressed 
patients were included in the random-effect meta-analysis 
and secondary analyses comparing outcome of studies with 
different parameters were conducted as well. Principal inclu-
sion criteria were: randomization in parallel or crossover 
design with sham, blinding of both patient and investigator, 
diagnosis of unipolar or bipolar depression (only in 1 study 
participants suffered from post-stroke depression) [37]. Stud-
ies had to report results by using the HRSD or the MARDS. 
Separate meta-analyses were conducted according to the 
classification of different studies in the following groups: 
mean age: < 50 versus  50 years; treatment resistance 
(yes/no); number of TMS sessions (5, 10, more than 10); 
type of depressive disorder; medications (stable or not); 
stimulation intensity (80%-100% or more than 100%); left 
DLPFC stimulation frequency (in some studies frequency 
was less than 15 Hz and in others more than 15 Hz); pres-
ence of psychotic features, etc... In order to assess the quality 
of each study, a specific rate according to Couturier’s criteria 
was performed as well. Results showed that rTMS was more 
effective than sham (with a large effect size of 0.071 and a 
mean reduction of depressive symptoms of 33.6%), without 
significant differences between studies previously included 
and excluded in Couturier’s meta-analysis. No significant 
relationship between trials quality and effect size was found. 
Probably due to the high variability in stimulation parame-
ters, variables that could clearly predict TMS response were 
not identified. Nevertheless, studies included patients on 
unstable medications and studies using intensity < 90% of 
the motor threshold may have resulted in lower level of effi-
cacy. DLPFC high frequency and low frequency appeared to 
be equally effective [38]. 
Gross and colleagues in 2007 [39] conducted a system-
atic review and meta-analysis to specifically investigate 
whether more recent studies (published from December 2005 
to November 2006) on rTMS in MD, using different parame-
ters of stimulation, have shown improved clinical results 
compared to previous meta-analyses. Inclusion criteria were 
similar to those used in the Martin’s meta-analysis and 5 
studies were included. Heterogeneity among these 5 trials 
consisted of the site and frequency of stimulation (bilateral 
stimulation in one study, low frequency right-sided rTMS in 
two studies and high frequency left-sided in the others), 
number of sessions (from 10 to 16), use of different outcome 
measures (e.g., one study used the MADRS while the others 
the HRSD) and different levels of treatment resistance. The 
quality of the overall analysis was significantly improved. 
The number of patients was 274, mean age 44.7 years, and 
female to male ratio 183:91. Of note, authors found a larger 
antidepressant effect of TMS when compared with previous 
studies, both in low-frequency right-sided [40] and in high-
frequency left-sided TMS [41, 42]. Of clinical interest, in 
relation to high-frequency, left-sided rTMS, there were sig-
nificant differences between previous metanalytic studies 
and this meta-analysis, particularly when considering the 
number of sessions (10 vs 15). In fact, it was shown that the 
number of sessions might be an important parameter to pre-
dict the clinical effect of rTMS. The same conclusion was 
reported from studies stimulating in low frequency, right 
side [43, 44]. Another potential difference in patient selec-
tion was that patients enrolled in more recent studies were 
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less refractory to medications and, therefore, more likely to 
respond. The comparison of the effect size of 2 studies of 
bilateral stimulation suggested that bilateral stimulation did 
not induce a larger effect size (0.59 and 0.84 vs 0.82 and 
1.49 for the 2 bilateral stimulation, unilateral left and unilat-
eral right stimulation studies, respectively). The possibility 
to draw any significant conclusion was limited by the small 
number of studies.  
The meta-analysis conducted by Lam and colleagues in 
2008 [45] systematically reviewed published studies with 
rTMS in patients affected by TRD, focusing on clinical out-
come. A total of 32 RCTs comparing rTMS with sham con-
trol were identified and 8 were excluded due to the lack of 
sham treatment [46-48], no definition of TRD [49, 50], or 
because the major aim of the studies was to analyze im-
provement of cognitive function or reduction of pain in pa-
tients with MD [51, 52], or multiple crossover with no data 
on the first treatment sequence [53]. One of the remaining 
studies did not report clinical response, remission rates and 
rating scales scores [54]. As a consequence, only 23 studies 
were available for quantitative analysis. The primary out-
come measure was clinical response, defined as the reduction 
 than 50% on HDRS or MADRS scores. Other outcome 
measures included clinical remission, defined as the presence 
of endpoint scale scores within the normal range and the 
standardized mean difference. Nine studies considered TRD 
as the failure of > 1 trial of antidepressants; the others as the 
failure of > 2. There was homogeneity of variables, with 
high frequency left-rTMS as the most common studied ac-
tive condition. Most of the studies used 1 to 2 weeks of 
treatment; 3 RCTs used 3 weeks and only 2 studies 4 weeks. 
In the majority of the studies, patients were taking concomi-
tant antidepressants, with dosages kept unchanged before 
and during rTMS. Only 4 studies included drug-free patients. 
In 2 studies, patients started a new antidepressant at the same 
time of TMS [55, 56]. Only 8 studies systematically fol-
lowed-up patients after completing the double-blind phase, 
usually in the short-term (1 to 3 weeks). Given that different 
studies reported that longer treatment period are associated 
with higher response rates, the principal limitation of this 
meta-analysis is the short term duration (1-2 weeks) of most 
studies. Results showed that antidepressant effects persisted 
for 1 to 2 weeks after TMS discontinuation. Two RCTs had 
longer follow-up periods: in the first one, rTMS was started 
together with 20 mg of escitalopram showing maintenance of 
rTMS response for 5 weeks but no difference was found at 9 
weeks [56]. The second did not show significant difference 
between active and sham at 5 weeks. Main results of this 
meta-analysis showed that active rTMS was significantly 
superior to sham treatment over short-term acute treatment 
of TRD (1-4 weeks). This meta-analysis also reported a good 
tolerability of rTMS, with few dropouts and side-effects. 
Despite this positive result, the overall response and remis-
sion rates were low and it was unclear whether rTMS effects 
were sustained.  
In 2009, Shutter et al. [57] published a meta-analysis that 
included a group of studies with high frequency rTMS over 
the left DLPFC in MD published between January 1980 and 
November 2007. A total of 30 double-blind sham-controlled 
studies were included with 1164 patients enrolled, 606 of 
whom received real rTMS and 558 sham treatment. The 
overall weighted mean effect size for treatment was 0.39 
showing that rTMS was significantly more effective than 
sham. Differences in the effect size between treatment resis-
tant and non-resistant patients were not found. Finally, the 
comparison of effect sizes between studies that applied 
stimulation intensities <100% MT (n = 14) and studies that 
used 100-120% intensities (n = 16) were not found, support-
ing the hypothesis that intensity of rTMS does not play a 
major role in term of antidepressant effect. The authors 
stressed a major methodological limitation in the revised 
studies which was the unavailability of an ideal sham condi-
tion; in fact, the procedure of sham stimulation used in many 
trials could have been partially active and the physician 
could not be really blind to it. 
Recently Shutter [58] conducted a systematic research in 
order to examine the efficacy of slow-frequency rTMS to the 
frontal cortex in MD. Included articles were identified 
through a literature search in the period between January 
1994 and July 2009. The author examined, in a random-
effect meta-analysis, 9 double-blind sham-controlled parallel 
intention-to-treat studies. The total sample included 252 pa-
tients with a mean age of 50 years. The mean number of 
treatment sessions in these studies was 9 (5 to 16 session) 
and the mean intensity of stimulation was 102%. The first 
aim of the study was to assess the efficacy of slow-frequency 
rTMS by analyzing the effects of sham vs real stimulation in 
depressed patients. The cumulative effect size for treatment 
was 0.63 which supported the efficacy of TMS. The second 
aim was to compare slow and fast-frequency stimulation, 
and results of this random-effect model analysis did not 
show any significant difference between the two procedures. 
The major limitations of this study was the small number of 
double-blind sham-controlled studies which might have un-
derpowered its results and the large variation of target stimu-
lation sites. Moreover, the available data were not suitable to 
determine effect sizes for low-frequency rTMS applied over 
the left and right frontal prefrontal cortex separately. 
Author’s conclusion was that slow-frequency was as effec-
tive as fast frequency, though generally better tolerated, al-
lowing longer and safer stimulation periods. 
Of note, Brunoni and colleagues [59] have recently 
(2009) published a meta-analysis in order to assess the mag-
nitude of the placebo response in MD. A literature search 
was performed from April 2002 to April 2008 and forty-one 
studies were included; 29 studies used TMS and 12 escitalo-
pram vs sham. Results showed a large placebo response for 
both TMS and escitalopram, suggesting that sham response 
is related with previous treatment refractoriness and with the 
use of TMS as add-on strategy, but not with other variables 
like age and gender 
In 2010, Slotema et al. [60] published a meta-analysis 
that included studies with rTMS in MD (n = 40), auditory 
verbal hallucinations (n = 7), negative symptoms of Schizo-
phrenia (n = 7), Obsessive-Compulsive Disorder (n = 3), 
Tourette’s Syndrome (n = 2), Panic Disorder (n = 1), Buli-
mia Nervosa (n = 1), Mania (n = 1) and Post-Traumatic 
Stress Disorder (n = 1). A literature search was performed 
from 1966 till 2008. With respect to rTMS in MD, studies 
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were divided in 2 groups: rTMS vs sham (34) and rTMS vs 
ECT (6). With respect to the first group, a total of 1347 pa-
tients was enrolled, 715 of whom received real rTMS and 
632 sham treatment. The mean weighted effect size for all 
studies was 0.55: for left-sided rTMS it was 0.53, for right-
sided rTMS 0.82 and, finally, for bilateral rTMS 0.47. TMS 
as a monotherapy (effect size = 0.96) was compared to rTMS 
started simultaneously with medication (effect size = 0.51) 
or during continuation of preexisting antidepressant treat-
ment as augmentation treatment (effect size = 0.37). With 
respect to the second group, a total of 215 patients was en-
rolled (113 treated with rTMS and 102 with ECT), showing 
greater efficacy for ECT, with a weighted effect size of 0.47. 
Results indicated that TMS was more effective than sham in 
the treatment of MD, but less effective than ECT. Moreover, 
there was a trend for rTMS for being more effective as 
monotherapy. Authors’ conclusion was that rTMS deserved 
a place in standard treatment for TRD and other psychiatric 
disorders.  
To date and to authors’ knowledge, 2 main meta-analyses 
have been specifically focused on the safety of rTMS. A 
meta-analysis conducted by Machii and colleagues in 2006 
[61] was aimed to assess the safety of rTMS applied over 
non-motor areas. A specific search of any adverse effect was 
conducted considering all articles published from January 
1998 to December 2003. Headache was the most common 
side effect, occurring in 23% of patients. Major side effects 
were rare and consisted of 2 seizures and 4 cases of psy-
chotic symptoms induced by left-sided rTMS. In one case of 
seizure, rTMS was applied to the left DLPFC at an intensity 
of 120% and a frequency of 15 Hz [62]. In the other, rTMS 
was applied over the left DLPFC at an intensity of 110% and 
a frequency of 20 Hz [63]. Taken as a whole, the frequency 
adopted in these two cases is higher than what is generally 
used (10 Hz). In conclusion, rTMS of non-motor areas ap-
peared to be safe with few and mild side-effects.  
A recent meta-analysis conducted by Janicak and col-
leagues in 2008 [64] assessed the safety of rTMS given that 
prior studies had given only limited importance to this as-
pect. In addition, the acute efficacy of rTMS and the duration 
of its benefit were analyzed. Three separate clinical protocols 
were included, with 325 patients from 23 clinical sites in the 
US, Australia and Canada. All studies concerned the use of 
rTMS in the treatment of MD. Safety assessment was con-
ducted in relation to side effects, cognitive functions and 
auditory threshold. TMS was administered in over 10000 
cumulative treatment sessions in this study program. Most 
frequent side effects were mild, such as headaches and scalp 
discomfort. No adverse events such as seizures were re-
ported. Auditory threshold and cognitive function did not 
change during the stimulation. Discontinuation rate due to 
adverse events was found to be around 4.5%. In conclusion, 
rTMS was well tolerated and associated with low incidence 
of side effects that were mostly mild to moderate. 
DISCUSSION 
The results of retrieved meta-analyses rise different ques-
tions about the state of art of TMS in MD. On one hand, it is 
clear that first meta-analyses showed mixed results on the 
efficacy of rTMS for the treatment of TRD [24, 26, 27]. In 
particular, the attention was focused on high frequency 
stimulation, that resulted fairly better than placebo [21]. In 
the following years, some doubts persisted about the real 
efficacy of the technique and many authors confirmed that 
there was insufficient evidence to view rTMS as effective 
treatment for depression [29, 34] and to predict treatment 
response [36], whereas other authors supported the antide-
pressant effect of rTMS [39, 56], particularly in the acute 
treatment [45]. On the other hand, the most recent meta-
analyses [58] seemed to support the efficacy of low fre-
quency rTMS and confirmed that low and rapid-rate rTMS 
are equally effective in the treatment of TRD. RTMS ques-
tioned efficacy in first meta-analyses may be explained tak-
ing into account the following factors. First of all, the low 
statistical power of many meta-analyses, which is related to 
the small size of the analyzed samples. Nevertheless, as 
Gross and colleagues showed in 2007, evidence from studies 
using high-frequency, left-sided rTMS showed significant 
differences compared with previous studies and, in this per-
spective, the meta-analysis by Gross stressed the importance 
of the number of sessions (10 vs 15 sessions). In fact, it has 
been shown that the number of sessions is an important pa-
rameter to predict the clinical effect of rTMS. The same con-
clusion was reported when it was stimulated the right pre-
frontal cortex at low frequency, with results comparable to 
the high-frequency, left-sided stimulation. Therefore, the 
duration of treatment is supposed to play a very important 
role in the antidepressant efficacy of rTMS. This aspect has 
been further stressed in a review by Loo and colleagues [65] 
that showed that 2-week treatment course provided only 
modest clinical outcomes and was additionally remarked by 
Daskalakis and coworkers in 2008 [66]. In the same perspec-
tive, O’Reardon and colleagues clearly showed that a course 
of stimulation longer than 2 weeks of rTMS is required for 
the achievement of significant improvement, observing, 
moreover, that 2 additional weeks of rTMS beyond the initial 
4 weeks could result in further clinical benefit [67].  
Other reasons for the modest efficacy of rTMS compared 
to sham stimulation include the different definitions used for 
TRD, as well as the different adopted procedures of sham 
stimulation and the use of different clinical outcome meas-
ures. To join a general consensus about research and clinical 
settings, safety, ethical consideration and stimulation pa-
rameters, safety and efficacy guidelines on brain stimulation 
and, in particular on TMS, have been recently edited [8, 68]. 
In fact, over the last years the number of applications of 
TMS has substantially increased, with the adjustment of pre-
vious paradigms and the development of novel ones (e.g., 
pattern repetitive TMS). Moreover, technical advances have 
led to new device design and to the integration of TMS with 
electroencefalography (EEG), positron emission tomography 
(PET) and functional magnetic resonance imaging (fMRI). 
Finally, treatment guidelines are necessary for safety reasons 
in order to establish appropriate and safe range of stimula-
tion in terms of frequency, intensity, etc… In fact, even 
though the occurrence of seizures has been extremely infre-
quent, it is definitely important to avoid this adverse event 
stimulating within safe parameters and excluding potential 
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risk factors [8]. On the other hand, if we can be optimistic 
about the efficacy of rTMS in the short-term treatment of 
MD and TRD, it is unclear whether these beneficial effects 
are sustained [36, 45, 69] given that follow-up studies are 
substantially lacking. 
In this perspective, a recent study has investigated the 
long-term efficacy of rTMS in bipolar patients, suggesting 
that immediate remission is predictive of sustained benefit 
after 1 year [69]. Another recent study conducted by Jani-
cack et al. [70] examined the persistence of rTMS benefits in 
a 24 weeks follow-up, finding that patients who benefited 
from acute treatment mainteined this effect in the long-term 
while on mainteinance antidepressant monotherapy.  
CONCLUSION 
Traditionally used in neurophysiology as a research tool, 
rTMS has been applied during the last decade in a variety of 
psychiatric disorders – mostly MD with treatment resistant 
features - as a potentially therapeutic intervention. Most of 
the work in this field has been carried out in drug-resistant 
patients with positive results emerging from recent meta-
analyses which analyzed studies using novel and more effec-
tive stimulation parameters (e.g., a greater number of ses-
sions). The multitude of parameters of stimulation implicated 
substantially different settings in many studies, but metana-
lytic indications help us to start to better define important 
practical aspects in rTMS treatment, such as the duration, 
stimulation target, frequency and definition of the degree of 
treatment resistance and of the predictors of response. Safety 
continues to be an important point favoring the clinical use 
of TMS, even though it is crucial that this intervention is 
provided by centers and clinicians with proven experience in 
the field. In terms of tolerability, it may be worthwhile to 
mention recent data from the Optimization of TMS for the 
Treatment of Depression (OPT-TMS) study, reporting a sig-
nificant decrease of procedural pain over time of left-
prefrontal rTMS for Depression. OPT-TMS is a 4 year, mul-
ticenter, double-blind, randomized, sham-controlled study 
with daily left prefrontal rTMS for MD, including 240 pa-
tients. Initial results from the open-label phase of this trial, in 
fact, suggest that painfulness of left prefrontal rTMS dimin-
ished of 48% over 3 weeks of daily treatment [71].  
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